Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chronic Fatigue Syndrome Drug Development Efforts Get A Boost From FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency is undertaking a series of activities with patients, advocacy groups and other stakeholders aimed at spurring development of new treatments. Hemispherx is hoping its investigational drug Ampligen, currently under FDA review, will become an early beneficiary of new statutory provisions on expedited approval.

You may also be interested in...



FDA Chronic Fatigue Guidance Takes Flexible Stand On Patient-Reported Outcomes

Clinical trial efficacy endpoints for investigational CFS/ME drugs should include patient-reported symptoms, but FDA is open to the use of instruments evaluated in other populations for this purpose, agency says in a new draft guidance.

Chronic Fatigue Syndrome Will Be First Of PDUFA V’s Disease Area Meetings

FDA is bringing an ongoing program to spur drug development for CFS and myalgic encephalomyelitis under the umbrella of the user fee program’s Patient-Focused Drug Development initiative, which calls for 20 patient-centric meetings over five years.

Hemispherx Vows To Fight FDA’s Second Rejection Of Ampligen

In a “complete response” letter, FDA requested at least one new clinical trial, along with nonclinical studies and numerous data analyses, before approval of the chronic fatigue syndrome drug. Hemispherx continues to assert the existing data support approval and plans an appeal to FDA’s Office of New Drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel